Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;132(2):419-421.
doi: 10.1002/lary.29964. Epub 2021 Nov 26.

New Onset of Smell and Taste Loss Are Common Findings Also in Patients With Symptomatic COVID-19 After Complete Vaccination

Affiliations

New Onset of Smell and Taste Loss Are Common Findings Also in Patients With Symptomatic COVID-19 After Complete Vaccination

Luigi A Vaira et al. Laryngoscope. 2022 Feb.

Abstract

The aim of this study is to investigate the clinical profile of patients who developed coronavirus disease 2019 (COVID-19) after full vaccination. Demographic, epidemiological and clinical data were collected through medical records and online patient-reported outcome questionnaire from patients who developed symptomatic SARS-CoV-2 infection, confirmed by nasopharyngeal swab, at least 2 weeks after completion of vaccination. A total of 153 subjects were included. The most frequent symptoms were: asthenia (82.4%), chemosensory dysfunction (63.4%), headache (59.5%), runny nose (58.2%), muscle pain (54.9%), loss of appetite (54.3%), and nasal obstruction (51.6%). Particularly, 62.3% and 53.6% of subjects reported olfactory and gustatory dysfunction, respectively. Symptom severity was mild or moderate in almost all cases. Chemosensory dysfunctions have been observed to be a frequent symptom even in subjects who contracted the infection after full vaccination. For this reason, the sudden loss of smell and taste could continue to represent a useful and specific diagnostic marker to raise the suspicion of COVID-19 even in vaccinated subjects. In the future, it will be necessary to establish what the recovery rate is in these patients. LEVEL OF EVIDENCE: 4 Laryngoscope, 132:419-421, 2022.

Keywords: COVID-19; ageusia; anosmia; gustatory dysfunction; olfactory dysfunction; vaccination.

PubMed Disclaimer

Comment in

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med 2020;383:2603–2615. - PMC - PubMed
    1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer‐BioNTech and Oxford‐AstraZeneca vaccines on covid‐19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case‐control study. BMJ 2021;373:n1088. - PMC - PubMed
    1. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid‐19 with the BNT162b2 and mRNA‐1273 vaccines. N Engl J Med 2021;385:320–329. - PMC - PubMed
    1. International group for the study of COVID‐19 related chemosensory dysfunctions . Investigation of the clinical manifestations of COVID‐19 in vaccinated subjects. Available at: https://www.surveymonkey.com/r/9Y39587. Accessed October 6, 2021.
    1. Lechien JR, Chiesa‐Estomba CM, Hans S, et al. Validity and reliability of the COVID‐19 symptom index, an instrument evaluating severity of general and otolaryngological symptoms. Acta Otolaryngol 2021;131:615–620. - PubMed

Substances